Brief: Trevena Announces Initial Topline OLINVYK Data From ~200 Patient Real-World Clinical Outcomes Study
30/03/2023 12:28
March 30 (Reuters) - Trevena Inc TRVN.O :
* TREVENA ANNOUNCES INITIAL TOPLINE OLINVYK DATA FROM ~200
PATIENT
REAL-WORLD CLINICAL OUTCOMES STUDY
* TREVENA INC - NO DRUG-RELATED SERIOUS ADVERSE EVENTS AND
NO
DEATHS WERE REPORTED IN VOLITION STUDY
* TREVENA INC - OLINVYK-TREATED PATIENTS HAD A STATISTICALLY
SIGNIFICANT 1.6 DAY (ABOUT 27%) REDUCTION IN AVERAGE OVERALL
HOSPITAL LENGTH OF STAY
Source text for Eikon: ID:nGNXb6Fdx3
Further company coverage: TRVN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Trevena
See all newsTrevena Inc reports results for the quarter ended in June - Earnings Summary
Trevena Inc expected to post a loss of 29 cents a share - Earnings Preview
Brief: Trevena Q2 EPS USD -0.23
Brief: Trevena Announces $2M Non-Dilutive Financing Tranche And Reduction In Outstanding Liabilities In Connection With Existing Ex-Us Royalty Financing
U.S. STOCKS ON THE MOVE-Allstate, MicroStrategy, AutoZone